EA
CYTK icon

Evolution Advisers’s Cytokinetics CYTK Stock Holding History

Evolution Advisers’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+1
New +$72 ﹤0.01% 391

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Evolution Advisers's CYTK Position: Q2 2026 in Review

Evolution Advisers opened a new position in Cytokinetics (CYTK) in Q2 2026: 1 share worth $0. The stake represents ﹤0.01% of the portfolio and ranks #391 among its holdings.

480 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Evolution Advisers held 1 share of Cytokinetics worth $0 as of Q2 2026.
  • Cytokinetics was a new Evolution Advisers position in Q2 2026.
  • Cytokinetics made up ﹤0.01% of Evolution Advisers's portfolio in Q2 2026, its #391 holding.
  • 480 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Evolution Advisers's 13F filing for Q2 2026, filed 31 Jul 2026.